Quercetin nanoparticles display antitumor activity via proliferation inhibition and apoptosis induction in liver cancer cells

International Journal of Oncology

Volumn 50, Issue 4, 2017, Pages 1299-1311

  Ren, Ke Wei ^a   Li, Ya Hua ^a   Wu, Gang ^a   Ren, Jian Zhuang ^a   Lu, Hui Bin ^a   Li, Zong Ming ^a   Han, Xin Wei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Antitumor; Apoptosis; Liver cancer; Proliferation; Quercetin nanoparticles

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; CYCLOOXYGENASE 2; CYTOCHROME C; DNA BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN AP 2BETA; PROTEIN KINASE B; QUERCETIN NANOPARTICLE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; ANTIOXIDANT; GOLD; NANOPARTICLE; PTGS2 PROTEIN, HUMAN; QUERCETIN; TELOMERASE; TFAP2B PROTEIN, HUMAN; TRANSCRIPTION FACTOR AP 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER CANCER; LIVER CANCER CELL LINE; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CELL MOTION; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; LIVER NEOPLASMS; METABOLISM; TUMOR CELL LINE;

ANTIOXIDANTS; APOPTOSIS; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYTOCHROMES C; DRUG DELIVERY SYSTEMS; GOLD; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; NANOPARTICLES; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; QUERCETIN; TELOMERASE; TRANSCRIPTION FACTOR AP-2;

EID: 85018494657     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2017.3886     Document Type: Article

References (44)

1. Marquardt JU, Andersen JB and Thorgeirsson SS: Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer 15: 653-667, 2015.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
3. Chatterjee R and Mitra A: An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer. Int Immunopharmacol 24: 335-345, 2015.
4. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, et al: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol 57: 821-829, 2012.
5. Davis JM, Murphy EA and Carmichael MD: Effects of the dietary flavonoid quercetin upon performance and health. Curr Sports Med Rep 8: 206-213, 2009.
6. Wiczkowski W, Romaszko J, Bucinski A, Szawara-Nowak D, Honke J, Zielinski H and Piskula MK: Quercetin from shallots (Allium cepa L. var. aggregatum) is more bioavailable than its glucosides. J Nutr 138: 885-888, 2008.
7. Guo Y, Mah E, Davis CG, Jalili T, Ferruzzi MG, Chun OK and Bruno RS: Dietary fat increases quercetin bioavailability in overweight adults. Mol Nutr Food Res 57: 896-905, 2013.
8. Aguirre L, Arias N, Macarulla MT, Gracia A and Portillo MP: Beneficial effects of quercetin on obesity and diabetes. Open Nutraceuticals J 4: 189-198, 2011.
9. Bhattacharyya SS, Paul S, De A, Das D, Samadder A, Boujedaini N and Khuda-Bukhsh AR: Poly (lactide-co-glycolide) acid nanoencapsulation of a synthetic coumarin: Cytotoxicity and bio-distribution in mice, in cancer cell line and interaction with calf thymus DNA as target. Toxicol Appl Pharmacol 253: 270-281, 2011.
10. Lee KM, Hwang MK, Lee DE, Lee KW and Lee HJ: Protective effect of quercetin against arsenite-induced COX-2 expression by targeting PI3K in rat liver epithelial cells. J Agric Food Chem 58: 5815-5820, 2010.
11. Tan J, Wang S, Yang J and Liu Y: Coupled particulate and continuum model for nanoparticle targeted delivery. Comput Struc 122: 128-134, 2013.
12. Wang S, Zhou Y, Tan J, Xu J, Yang J and Liu Y: Computational modeling of magnetic nanoparticle targeting to stent surface under high gradient field. Comput Mech 53: 403-412, 2014.
13. Puhl AC, Fagundes M, dos Santos KC, Polikarpov I, das Gracas MF, da Silva F, Fernandes JB, Vieira PC and Forim MR: Preparation and characterization of polymeric nanoparticles loaded with the flavonoid luteolin, by using factorial design. Int J Drug Deliv 3: 683-698, 2011.
14. Pinzón-Daza ML, Campia I, Kopecka J, Garzón R, Ghigo D and Riganti C: Nanoparticle-and liposome-carried drugs: New strategies for active targeting and drug delivery across blood-brain barrier. Curr Drug Metab 14: 625-640, 2013.
15. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S and Wood MJ: Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29: 341-345, 2011.
16. Xie Y, Ye L, Zhang X, Cui W, Lou J, Nagai T and Hou X: Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: In vitro and in vivo studies. J Control Release 105: 106-119, 2005.
17. Hosta-Rigau L, Schattling P, Teo BM, Lynge ME and Städler B: Recent progress of liposomes in nanomedicine. J Mater Chem B Mater Biol Med 2: 6686-6691, 2014.
18. Sapra P and Allen TM: Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 42: 439-462, 2003.
19. Zheng YL, Zhang F, Sun B, Du J, Sun C, Yuan J, Wang Y, Tao L, Kota K, Liu X, et al: Telomerase enzymatic component hTERT shortens long telomeres in human cells. Cell Cycle 13: 1765-1776, 2014.
20. Kuźbicki L, Lange D, Stanek-Widera A and Chwirot BW: Different expression of cyclooxygenase-2 (COX-2) in selected nonmelanocytic human cutaneous lesions. Folia Histochem Cytobiol 49: 381-388, 2011.
21. Müller-Decker K: Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: Pharmacological, genetic, and clinical evidence. Cancer Metastasis Rev 30: 343-361, 2011.
22. Han S, Lee JH, Kim C, Nam D, Chung WS, Lee SG, Ahn KS, Cho SK, Cho M and Ahn KS: Capillarisin inhibits iNOS, COX-2 expression, and proinflammatory cytokines in LPS-induced RAW 264.7 macrophages via the suppression of ERK, JNK, and NF-κB activation. Immunopharmacol Immunotoxicol 35: 34-42, 2013.
23. Hsiang CY, Lo HY, Huang HC, Li CC, Wu SL and Ho TY: Ginger extract and zingerone ameliorated trinitrobenzene sulphonic acid-induced colitis in mice via modulation of nuclear factor-κB activity and interleukin-1β signalling pathway. Food Chem 136: 170-177, 2013.
24. Wang J, Xiao X, Zhang Y, Shi D, Chen W, Fu L, Liu L, Xie F, Kang T, Huang W, et al: Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res 53: 77-90, 2012.
25. Tsao R: Chemistry and biochemistry of dietary polyphenols. Nutrients 2: 1231-1246, 2010.
26. Dong YS, Wang JL, Feng DY, Qin HZ, Wen H, Yin ZM, Gao GD and Li C: Protective effect of quercetin against oxidative stress and brain edema in an experimental rat model of subarachnoid hemorrhage. Int J Med Sci 11: 282-290, 2014.
27. Kobori M, Takahashi Y, Sakurai M, Akimoto Y, Tsushida T, Oike H and Ippoushi K: Quercetin suppresses immune cell accumulation and improves mitochondrial gene expression in adipose tissue of diet-induced obese mice. Mol Nutr Food Res 60: 300-312, 2016.
28. Iyer AK, Khaled G, Fang J and Maeda H: Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 11: 812-818, 2006.
29. Cho HJ, Yoon HY, Koo H, Ko SH, Shim JS, Lee JH, Kim K, Kwon IC and Kim DD: Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumortargeted delivery of docetaxel. Biomaterials 32: 7181-7190, 2011.
30. Sharma VK, Mishra D, Sharma A and Srivastava B: Liposomes: Present prospective and future challenges. Int J Current Pharm Rev Res 1: 6-16, 2010.
31. Barré B and Perkins ND: A cell cycle regulatory network controlling NF-kappaB subunit activity and function. EMBO J 26: 4841-4855, 2007.
32. Fu Y, Kadioglu O, Wiench B, Wei Z, Gao C, Luo M, Gu C, Zu Y and Efferth T: Cell cycle arrest and induction of apoptosis by cajanin stilbene acid from Cajanus cajan in breast cancer cells. Phytomedicine 22: 462-468, 2015.
33. Satyanarayana A, Hilton MB and Kaldis P: p21 Inhibits Cdk1 in the absence of Cdk2 to maintain the G1/S phase DNA damage checkpoint. Mol Biol Cell 19: 65-77, 2008.
34. Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B, Crook T, Inga A, Resnick MA, Iggo R, et al: p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 20: 3573-3579, 2001.
35. Chien CS, Shen KH, Huang JS, Ko SC and Shih YW: Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells. Mol Cell Biochem 333: 169-180, 2010.
36. Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, Chen LZ, Tan HX, Li W, Bi J, et al: Involvement of PI3K/PTEN/ AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res 39: 177-186, 2009.
37. Choi SH, Im E, Kang HK, Lee JH, Kwak HS, Bae YT, Park HJ and Kim ND: Inhibitory effects of costunolide on the telomerase activity in human breast carcinoma cells. Cancer Lett 227: 153-162, 2005.
38. Kim MO, Moon DO, Kang SH, Heo MS, Choi YH, Jung JH, Lee JD and Kim GY: Pectenotoxin-2 represses telomerase activity in human leukemia cells through suppression of hTERT gene expression and Akt-dependent hTERT phosphorylation. FEBS Lett 582: 3263-3269, 2008.
39. Di Stefano AL, Enciso-Mora V, Marie Y, Desestret V, Labussière M, Boisselier B, Mokhtari K, Idbaih A, Hoang-Xuan K, Delattre JY, et al: Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies. Neuro-oncol 15: 542-547, 2013.
40. Deng WG, Jayachandran G, Wu G, Xu K, Roth JA and Ji L: Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding protein-2beta in human lung cancer cells. J Biol Chem 282: 26460-26470, 2007.
41. Kajita S, Ruebel KH, Casey MB, Nakamura N and Lloyd RV: Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Mod Pathol 18: 221-227, 2005.
42. Wang D and Dubois RN: The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29: 781-788, 2010.
43. Deng WG, Zhu Y and Wu KK: Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood 103: 2135-2142, 2004.
44. Fu L, Chen W, Guo W, Wang J, Tian Y, Shi D, Zhang X, Qiu H, Xiao X, Kang T, et al: Berberine Targets AP-2/hTERT, NF-κB/ COX-2, HIF-1α/VEGF and Cytochrome-c/caspase signaling to suppress human cancer cell growth. PLoS One 8: e69240, 2013.